Tratamiento con toxina botulínica en un entorno de recursos limitados: experiencias de una institución pública.

Saved in:

Bibliographic Details
Title:	Tratamiento con toxina botulínica en un entorno de recursos limitados: experiencias de una institución pública.
Alternate Title:	Botulinum toxin treatment in a resource-limited setting: Experiences from a public institution in a developing country.
Authors:	Panesso, Gloria Andrea^1,2, Martínez, Juan Diego³, Velasco, Annelise³ avap96@gmail.com, Forero, Stefanía³, Perdomo, Daniel³, Villamil, Ángela³, González, Edna Rocío³, Jiménez, Claudio Alejandro³
Source:	Biomédica: Revista del Instituto Nacional de Salud. sep2025, Vol. 45 Issue 3, p390-405. 16p.
Subjects:	BOTULINUM toxin, BOTULINUM A toxins, MEDICAL specialties & specialists, DRUG interactions, LATIN American studies
Abstract (English):	Introduction. Botulinum toxins have at least 30 therapeutic indications across different medical specialties. Some Latin American studies have described the experience of applying botulinum toxin in isolated clinical contexts. However, researchers have yet to provide comprehensive analysis about its use across diverse clinical indications. Objective. To classify the therapeutic use of botulinum toxin in a public health center in Bogotá, identifying the risks of pharmacological interactions and possible barriers related to its use. This knowledge will promote a better understanding of the indications, practices, and regulations regarding the use of the botulinum toxin in the Colombian context. Materials and methods. A cross-sectional study was conducted to analyze the use of botulinum toxin in a public institution in Bogotá, Colombia, applying the prescriptionindication methodology. Sociodemographic, clinical, and pharmacoepidemiologic data were extracted from medical records and the electronic prescription database Mi prescripción. A bivariate statistical analysis was performed using JAMOVI software, version 2.2.5. Results. A total of 197 patients received a prescription for botulinum toxin. Although the main indication was temporomandibular joint disorder, 70.6% of the prescriptions were classified under neurological conditions. In pediatric patients, the main indication was spastic cerebral palsy (90%). Most described clinical uses (92.4%) were aligned with the indications approved by the Instituto Nacional de Vigilancia de Medicamentos y Alimentos de Colombia. Risks of drug interactions were identified in 30.9% of the cases and were significantly associated with an anticholinergic load (p < 0.001). Conclusions. Botulinum toxin is used for multiple indications in multiple medical specialties. There is consistency between prescription and indication of the medication recommended by regulatory entities. Reviewing patient's pharmacological history is essential before prescribing botulinum toxin to reduce the risk of drug interactions. [ABSTRACT FROM AUTHOR]
Abstract (Spanish):	Introducción. La toxina botulínica se destaca por sus múltiples aplicaciones terapéuticas; tiene más de 30 indicaciones reconocidas en distintas especialidades. Sin embargo, a pesar de los estudios realizados en Latinoamérica, no hay una caracterización integral sobre su amplio espectro de uso clínico. Objetivo. Clasificar el uso farmacoterapéutico de la toxina botulínica en un centro de salud público de Bogotá, para identificar los riesgos de interacciones farmacológicas con otros compuestos y las posibles barreras para su uso. Se pretende fomentar una mejor comprensión de las indicaciones, prácticas y regulaciones de la toxina botulínica en el contexto colombiano. Materiales y métodos. Se realizó un estudio transversal en el que se analizó la administración de la toxina botulínica mediante la metodología de prescripción-indicación. Se recopiló información de las historias clínicas y del sistema de prescripción electrónica "Mi prescripción". Para el análisis de los datos, se utilizó el software estadístico JAMOVI, versión 2.2.5. Resultados. De 197 pacientes tratados con la toxina botulínica, la mayoría de las prescripciones se registraron bajo la categoría de trastornos neurológicos (70,6 %), aunque la indicación más frecuente correspondió a alteraciones de la articulación temporomandibular (18,8 %). En niños, la indicación predominante fue la parálisis cerebral espástica (90 %). El 92,4 % de las aplicaciones clínicas coincidieron con las aprobadas por el Instituto Nacional de Vigilancia de Medicamentos y Alimentos de Colombia. Se identificaron riesgos de interacciones farmacológicas en el 30,9 % de los casos, asociadas significativamente con una carga anticolinérgica (p < 0,001). Conclusión. La toxina botulínica es ampliamente utilizada en Colombia debido a sus diversas indicaciones clínicas. En general, se encontró una buena correspondencia entre las prescripciones y las recomendaciones de las guías reguladoras. Es crucial evaluar los antecedentes farmacológicos de los pacientes para minimizar el riesgo de interacciones farmacológicas. Se subraya la necesidad de revisar y ajustar la normativa sobre el uso de la toxina botulínica en el país. [ABSTRACT FROM AUTHOR]
	Copyright of Biomédica: Revista del Instituto Nacional de Salud is the property of Instituto Nacional de Salud of Colombia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	MedicLatina

Description
Abstract:	Introduction. Botulinum toxins have at least 30 therapeutic indications across different medical specialties. Some Latin American studies have described the experience of applying botulinum toxin in isolated clinical contexts. However, researchers have yet to provide comprehensive analysis about its use across diverse clinical indications. Objective. To classify the therapeutic use of botulinum toxin in a public health center in Bogotá, identifying the risks of pharmacological interactions and possible barriers related to its use. This knowledge will promote a better understanding of the indications, practices, and regulations regarding the use of the botulinum toxin in the Colombian context. Materials and methods. A cross-sectional study was conducted to analyze the use of botulinum toxin in a public institution in Bogotá, Colombia, applying the prescriptionindication methodology. Sociodemographic, clinical, and pharmacoepidemiologic data were extracted from medical records and the electronic prescription database Mi prescripción. A bivariate statistical analysis was performed using JAMOVI software, version 2.2.5. Results. A total of 197 patients received a prescription for botulinum toxin. Although the main indication was temporomandibular joint disorder, 70.6% of the prescriptions were classified under neurological conditions. In pediatric patients, the main indication was spastic cerebral palsy (90%). Most described clinical uses (92.4%) were aligned with the indications approved by the Instituto Nacional de Vigilancia de Medicamentos y Alimentos de Colombia. Risks of drug interactions were identified in 30.9% of the cases and were significantly associated with an anticholinergic load (p < 0.001). Conclusions. Botulinum toxin is used for multiple indications in multiple medical specialties. There is consistency between prescription and indication of the medication recommended by regulatory entities. Reviewing patient's pharmacological history is essential before prescribing botulinum toxin to reduce the risk of drug interactions. [ABSTRACT FROM AUTHOR]
ISSN:	01204157
DOI:	10.7705/biomedica.7383